Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.2B
51M shares
52-week range
$25.36 – $44.38
95% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
www.atricure.comNo one on the platform currently holds ATRC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 308,700 | $8.8M |
| Bridgewater Associatesas of 2026-03-31 | 33,517 | $956.2K |
No one on the platform has traded ATRC yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $ATRC
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-23-atricure-inc-stock/ $ATRC AtriCure Earnings Transcript
View on StockTwits ↗$ATRC Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.18 up 238.46% YoY • Reported revenue of $153.6M up 12.83% YoY • AtriCure projects full year 2026 revenue of approximately $602 million to $610 million, adjusted EBITDA of $85 million to $89 million, and adjusted earnings per share of $0.24 to $0.32.
View on StockTwits ↗$ATRC reports after the close, Estimize Consensus +0.02 EPS and +2.52M Revs compared to WS http://www.estimize.com/atrc/fq2-2026?utm_conten
View on StockTwits ↗$ATRC AtriCure to Announce Second Quarter 2026 Financial Results https://marketwirenews.com/stock/atrc/news/atricure-to-announce-second-quarter-2026-financial-r-8194777983968724.html?utm_source=stocktwits
View on StockTwits ↗$EW got FDA OK for heart clip; it enters a market led by $ATRC, adding competition but not changing the outlook much. https://notreload.xyz/xy/edwards-ecliptis-fda-clearance-challenges-atricure-atriclip/
View on StockTwits ↗$ATRC this is one of those classic cases of excellent company -> only a few hundred ST followers.
View on StockTwits ↗$ATRC these same conditions are basically true today. Reentering this very solid company
View on StockTwits ↗https://marketbeat.com/a/8650911/ $ATRC AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
View on StockTwits ↗$ATRC Ready and waiting for this one to rebound
View on StockTwits ↗$ATRC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $141.25M up 14.26% YoY • AtriCure projects full year 2026 revenue of $600M to $610M, Adjusted EBITDA of $80M to $82M, and adjusted earnings per share between $0.00 and $0.04, expecting continued positive cash flow.
View on StockTwits ↗$ATRC reports after the close, Estimize Consensus +0.01 EPS and +0.72M Revs compared to WS http://www.estimize.com/atrc/fq1-2026?utm_conten
View on StockTwits ↗$ATRC Share Price: $28.47 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $4.25 – $5.25 Target Zone: $7.34 – $8.97 Potential Upside: 63% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $606M | +13.6% | $0.11 | $0.05–$0.16 | 405.9× | 6 |
| 2027 | $680M | +12.1% | $0.42 | $0.37–$0.47 | 103.9× | 7 |
| 2028 | $765M | +12.5% | $0.70 | $0.41–$1.02 | 62.5× | 7 |
| 2029 | $851M | +11.3% | $0.73 | $0.72–$0.74 | 59.6× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $-0.00 | $0.18 | +10878.4% |
| 2026-05-05 | $-0.07 | $0.00 | +103.1% |
| 2026-02-17 | $-0.04 | $0.06 | +249.9% |
| 2025-10-29 | $-0.11 | $-0.01 | +90.9% |
| 2025-07-29 | $-0.15 | $-0.02 | +86.7% |
| 2025-04-29 | $-0.25 | $-0.14 | +44.0% |
| 2025-02-12 | $-0.23 | $-0.08 | +65.2% |
| 2024-10-29 | $-0.20 |
| $-0.17 |
| +15.0% |
| $1.6B |
| — |
| LMATLeMaitre Vascular, Inc. | $81.93 | -0.24% | $1.9B | — |
| NVCRNovocure Ltd | $17.38 | -1.19% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry